B. burgdorferi-specific antibody levels showed the same specificity as CXCL13 but lower sensitivity (85.7%) because two false-negative results were obtained, presumably owing to the delay in ...

Here we demonstrate that both the chemokine CXCL13 and the chemokine CCL21 attracted LTi cells at embryonic days 12.5–14.5 ... Antibody specificity was ensured by the use of isotype-matched ...

The reason for the high specificity is that CXCL13 is only released when surface proteins of B. burgdoferi react with cells of the immune system – long before antibodies against the bacterium ...

A team led by UCSF scientists has determined how the weapons producers of the immune system - the B cells that make antibodies - find the T cells they must team up with to attack invading pathogens.

CXCL13 is a well-described cell attractant via the CXCL13/CXCR5 axis. Intriguingly, CXCL13 ... CXCL13 antibody for the treatment of autoimmune disorders. BMC Immunol 16:6, 2015. Crossref. PubMed.

The CXCL13 chemokine ... that CXCL13 might be a particularly useful early marker of Lyme neuroborreliosis before positive tests for intrathecal antibodies because CXCL13 is secreted after ...

Background: Immune checkpoint inhibitors (ICIs), such as anti-PD-1/PD-L1 antibodies, have emerged as a successful immunotherapeutic strategy for advanced and metastatic urothelial cancer (UC).